| An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC) NCT06910137 | no aplica | Disponible por acceso ampliado |
| Cáncer de endometrio NCT04463771 | Fase 2 | Completado |
| Cáncer de cabeza y cuello NCT05287113 | Fase 2 | Completado |
| Tumor sólido metastásico NCT03059823 | Fase 1 | Completado |
| Carcinoma urotelial NCT04586244 | Fase 2 | Interrumpido |
| POD1UM-304 NCT04205812 | Fase 3 | Completado |
| Cáncer de pulmón no microcítico NCT04203511 | Fase 3 | Retirado antes de empezar |
| INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors NCT03589651 | Fase 1 | Completado |
| A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) NCT03599713 | Fase 2 | Completado |
| Tumor sólido avanzado, Tumor sólido metastásico NCT03910530 | Fase 1 | Completado |
| Melanoma metastásico NCT03679767 | Fase 2 | Completado |
| A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) NCT03597295 | Fase 2 | Completado |
| INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) NCT03920839 | Fase 1 | Retirado antes de empezar |